edrecolomab
rituximab
trastuzumab
gemtuzumab ozogamicina
cetuximab
bevacizumab
panitumumab
catumaxomab
ofatumumab
ipilimumab
brentuximab vedotin
pertuzumab
trastuzumab emtansina
obinutuzumab
dinutuximab beta
nivolumab
pembrolizumab
blinatumomab
ramucirumab
no citumumab
elotuzumab
daratumumab
mogamulizumab
inotuzumab ozogamicina
olaratumab
durvalumab
bermekimab
avelumab
atezolizumab
cemiplimab
moxetumomab pasudotox
tafasitamab
enfortumab vedotin
polatuzumab vedotin
isatuximab
belantamab mafodotin
dostarlimab
trastuzumab drukstecan
otros fármacos antineoplásicos